Clinical trials: Stage II Breast Carcinoma
Breast Cancer
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET) Information in Subtype of Metastatic Breast Cancer
- Trial name
- NCT04758416
- Testing
- biopsy or surgical pathology in metastases, 68Ga-HER2 affibody,18F-FDG, 18F-FES
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fudan University
Breast Neoplasms
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Pemetrexed is a multi-targeted anti-folate, that is used for non-small cell lung cancer and mesothelioma. There are several clinical studies of pemetrexed in breast cancer, but these are largely done before the wide use of…
- Trial name
- NCT03242616
- Testing
- Pemetrexed + Vinorelbine, Vinorelbine
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Breast Neoplasms
Breast Cancer, Reasoning, and Activity Intervention
This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a…
- Conditions
- Breast Cancer, Breast Neoplasms, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- BRAIN (NCT04816006)
- Testing
- Aerobic Exercise Training, Health Education (Active comparator)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Mayo Clinic
Cancer-related Problem/Condition, Cognitive Impairment
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of…
- Trial name
- NCT04669301
- Testing
- MAAT-G, Supportive therapy (time and attention control)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Rochester
Metastatic Breast Cancer
Ixabepilone + Carboplatin Metastatic Breast Cancer
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are…
- Trial name
- NCT01075100
- Testing
- Ixabepilone, Carboplatin
- Where
- 59 sites in United States
- Volunteers
- 103 people
- Sponsor
- US Oncology Research
Breast Cancer
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy.
- Trial name
- NCT02491892
- Testing
- Pertuzumab
- Where
- 18 sites in Australia, Belgium and 6 more
- Volunteers
- 79 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
- Trial name
- NCT00463034
- Testing
- microarray analysis, polymerase chain reaction, polymorphism analysis
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- University of Sheffield
Breast Cancer
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models.
- Trial name
- NCT00216047
- Testing
- PTK787, Trastuzumab
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Hoosier Cancer Research Network
Breast Cancer, Metastatic Triple Negative
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the patient and areas of cancer in their body that did not receive radiation therapy.
- Trial name
- NCT02730130
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
HER2 is a protein that sits on the surface of breast cancer cells in some people. Because you are one of these people, your breast cancer is called "HER2-positive." The HER2 protein is involved in the growth of your breast…
- Trial name
- NCT00721630
- Testing
- capecitabine, lapatinib
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer.
- Trial name
- NCT02788981
- Testing
- Mifepristone, Nab-Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Chicago
Breast Cancer
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
- Trial name
- NCT00887575
- Testing
- Paclitaxel, Carboplatin, Sunitinib
- Where
- 14 sites in United States
- Volunteers
- 54 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Colorectal Cancer, Melanoma
A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)
Evaluation and exploration of the phase I/II clinical safety and efficacy of personalized FAST(Radiation fueled antigens stimulated T-cell immunotherapy )cancer vaccine combined with radiotherapy.
- Conditions
- Breast Cancer, Colorectal Cancer, Melanoma, Lung Cancer
- Trial name
- FAST-CR (NCT06756295)
- Testing
- individualized tumor FAST vaccine combination (including adjuvant)
- Volunteers
- 154 people
- Sponsor
- Fengming Kong
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic…
- Trial name
- TRANSCENDER (NCT05744375)
- Testing
- Trastuzumab deruxtecan
- Where
- 19 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Spanish Breast Cancer Research Group
Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the…
- Trial name
- NCT06942234
- Testing
- JSKN016, Capecitabine, Paclitaxel (albumin bound)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Breast Cancer
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
The purpose of this study is to determine the efficacy of neoadjuvant treatment with pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide +/- trastuzumab followed by docetaxel in patients with locally advanced…
- Trial name
- NCT01206881
- Testing
- pegylated liposomal doxorubicin
- Where
- 4 sites in Denmark
- Volunteers
- 45 people
- Sponsor
- Herlev Hospital
Advanced Breast Cancer
Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
To explore the duration of continued treatment for patients with advanced breast cancer who achieve complete response assessed by PET-CT after receiving systemic anti-tumor therapy.
- Trial name
- NCT07888556
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.